ClearPoint Neuro Inc vs Wayfair Inc — how do they compare? ClearPoint Neuro Inc trades at $14.92 (market cap $444.14M), while Wayfair Inc trades at $103.55 (market cap $14.14B). The key difference: Wayfair Inc is far larger — about 31.8× ClearPoint Neuro Inc's market cap, and Wayfair Inc is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| CLPT | W | |
|---|---|---|
Market Cap | $444.14M | $14.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.60 | $119.05 |
52-Week Low | $8.66 | $57.40 |
Enterprise Value | $478.72M | $16.48B |
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $14.21, up 6.12% today, amid mixed technical signals and challenging fundamentals. The company reported Q2 2026 revenue growth but missed earnings expectations with a loss of $0.38 per share, continuing a trend of negative profitability. Despite 100% analyst buy ratings, financial metrics show significant losses with a net income margin of -81.76% and negative cash flow from operations of $30 million projected for 2026.
The investment case hinges on regulatory progress and partnership developments in neurotechnology, but substantial execution risks and persistent losses present headwinds. While analyst consensus remains bullish on long-term potential, current financial performance suggests cautious optimism is warranted until profitability improves.
Wayfair (W) trades at $106.59, up 2.44% today, showing strong momentum following better-than-expected Q2 2026 earnings. Technical indicators signal a bullish trend with the stock approaching key resistance levels. Fundamentally, the company delivered 7.5% year-over-year revenue growth in Q2 2026, though it continues to operate at a net loss margin of -2.49%. Recent news highlights strong U.S. segment performance and market share gains despite international challenges.
The outlook remains cautiously optimistic with analysts projecting 51.78% buy ratings and a $122 consensus price target, representing 14.4% upside potential. Key risks include persistent unprofitability, high debt-to-asset ratio of 95.11%, and uneven consumer demand. The stock's premium valuation at 151.17x EV/EBITDA requires continued execution on growth and margin expansion targets to justify current levels.
Trailing returns across standard periods
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →